BlackRock Cuts Edwards Lifesciences Stake to 6.0%
Ticker: EW · Form: SC 13G/A · Filed: Jan 25, 2024 · CIK: 1099800
| Field | Detail |
|---|---|
| Company | Edwards Lifesciences Corp (EW) |
| Form Type | SC 13G/A |
| Filed Date | Jan 25, 2024 |
| Risk Level | medium |
| Sentiment | mixed |
Complexity: simple
Sentiment: mixed
Topics: institutional-ownership, stake-change, medical-devices
TL;DR
**BlackRock trimmed its Edwards Lifesciences stake to 6.0%, signaling a potential shift in their investment view.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 25, 2024, disclosing its ownership in Edwards Lifesciences Corp. As of December 31, 2023, BlackRock reported beneficial ownership of 37,212,477 shares of Common Stock, representing 6.0% of the company's outstanding shares. This is a decrease from their previous filing, indicating BlackRock has reduced its stake in Edwards Lifesciences, which could signal a shift in their investment strategy or outlook for the medical device company.
Why It Matters
This matters to investors because a major institutional investor like BlackRock reducing its stake could suggest a less bullish outlook on Edwards Lifesciences' future performance, potentially influencing other investors' decisions.
Risk Assessment
Risk Level: medium — A large institutional investor reducing its stake can sometimes precede a period of underperformance for the stock, posing a medium risk to current shareholders.
Analyst Insight
An investor might consider researching the reasons behind BlackRock's reduction in stake, such as any recent company news or industry trends, before making any investment decisions regarding Edwards Lifesciences Corp.
Key Numbers
- 37,212,477 — Shares Beneficially Owned (This is the total number of Edwards Lifesciences shares BlackRock reported owning as of December 31, 2023.)
- 6.0% — Percentage of Class (This represents the proportion of Edwards Lifesciences' Common Stock that BlackRock beneficially owns, indicating a significant but reduced stake.)
- 11 — Amendment Number (This is the 11th amendment to BlackRock's Schedule 13G filing for Edwards Lifesciences, suggesting ongoing adjustments to their position.)
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Edwards Lifesciences Corp (company) — the subject company in which BlackRock holds shares
- 37,212,477 (dollar_amount) — number of shares beneficially owned by BlackRock
- 6.0% (dollar_amount) — percentage of Edwards Lifesciences' outstanding shares owned by BlackRock
- December 31, 2023 (dollar_amount) — date of the event requiring the filing
Forward-Looking Statements
- Edwards Lifesciences' stock price may experience short-term volatility due to BlackRock's reduced stake. (Edwards Lifesciences Corp) — medium confidence, target: Q1 2024
- Other institutional investors might re-evaluate their positions in Edwards Lifesciences following BlackRock's move. (Institutional Investors) — medium confidence, target: Q2 2024
FAQ
What is the purpose of an SC 13G/A filing?
An SC 13G/A is an amendment to a Schedule 13G filing, used by institutional investors like BlackRock to report changes in their beneficial ownership of 5% or more of a company's stock, as required by the Securities Exchange Act of 1934. This specific filing is Amendment No. 11 for BlackRock's stake in Edwards Lifesciences Corp.
Who is the reporting person in this filing?
The reporting person, or the entity filing the statement, is BlackRock Inc., located at 50 Hudson Yards, New York, NY 10001. They are a major asset manager.
What company's stock is the subject of this filing?
The subject company is Edwards Lifesciences Corp, a company in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry (SIC 3842), with its business address at One Edwards Way, Irvine, CA 92614.
How many shares of Edwards Lifesciences Corp. Common Stock does BlackRock Inc. beneficially own as of the filing date?
As of December 31, 2023, BlackRock Inc. beneficially owns 37,212,477 shares of Edwards Lifesciences Corp. Common Stock, representing 6.0% of the class.
What is the CUSIP number for Edwards Lifesciences Corp. Common Stock?
The CUSIP number for Edwards Lifesciences Corp. Common Stock is 28176E108, as stated in the filing.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 25, 2024 regarding Edwards Lifesciences Corp (EW).